Novavax | NVAX - Betriebsaufwand





Betriebsaufwand Veränderung Datum
Adma Biologics USD 76.41M 6.8M 2025-12
Agenus USD 19.81M 293.94M 2025-12
AstraZeneca USD 12.53B 4.16B 2025-12
BioCryst Pharmaceuticals USD 146.17M 534.06M 2025-12
Cassava Sciences USD 13.55M 1.69M 2025-12
Geron USD 58.8M 2.31M 2025-12
GlaxoSmithKline GBP 7.18B 1.42B 2025-12
MannKind USD 119.64M 56.29M 2025-12
Merck USD 10.16B 558M 2025-12
Minerva Neurosciences USD 4.52M 155.46K 2024-12
Moderna USD 1.54B 259M 2025-12
Novartis USD 9.8B 23M 2025-12
Novavax USD 126.2M 23.62M 2025-12
Pfizer USD 12.91B 79.89B 2025-12
Sanofi EUR 10.51B 1.21B 2025-12
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
TG Therapeutics USD 142.08M 9.74M 2025-12